PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER (PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER).
Prismasol B22GK 4/2.5 is a hemofiltration solution used for continuous renal replacement therapy (CRRT). It provides electrolytes and buffer to correct metabolic acidosis and maintains electrolyte balance while removing waste products via convective and diffusive clearance.
| Metabolism | Not metabolized; components are distributed and excreted renally during CRRT. |
| Excretion | PRISMASOL B22GK 4/2.5 is a hemodialysis solution; its components are primarily removed via dialysis. Electrolytes and lactate are eliminated renally in patients with residual function, but in ESRD, clearance is via dialysis. Glucose is metabolized or removed by dialysis. |
| Half-life | Not applicable as a dialysis solution. Individual components have varying half-lives: glucose ~1.5-2 h, lactate ~0.5-1.5 h, electrolytes depend on renal function. |
| Protein binding | Minimal (<5%) for electrolytes and lactate; glucose is not protein bound. |
| Volume of Distribution | Vd for solutes approximates total body water (0.6 L/kg); electrolytes distribute accordingly. |
| Bioavailability | Intravenous administration only via dialyzer; bioavailability is 100% as it is directly infused into the bloodstream. |
| Onset of Action | Immediate upon initiation of dialysis; correction of electrolyte and acid-base imbalances begins within minutes. |
| Duration of Action | Duration equals dialysis session length (typically 4-6 hours). Effects on electrolytes and acid-base balance persist until next dialysis. |
Continuous renal replacement therapy (CRRT) solution; dosing based on prescribed effluent rate, typically 20-35 mL/kg/h. Route: intravenous via CRRT circuit.
| Dosage form | INJECTABLE |
| Renal impairment | Not applicable; PRISMASOL is used for renal replacement therapy and dosing is independent of native renal function. |
| Liver impairment | No specific adjustment recommended; monitor electrolytes and acid-base status in hepatic impairment. |
| Pediatric use | Dosing based on weight and effluent rate: typical initial rate 2000-3000 mL/1.73 m²/h (or 20-30 mL/kg/h) for children; adjust per clinical response. |
| Geriatric use | No specific dose adjustment; monitor for fluid and electrolyte imbalances due to age-related decreased renal reserve. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER (PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER).
| Breastfeeding | Prismasol B22GK 4/2.5 is not systemically absorbed; therefore, excretion into breast milk is negligible. M/P ratio is not applicable. Breastfeeding is considered safe during maternal use of this solution. |
| Teratogenic Risk | Prismasol B22GK 4/2.5 is a hemodialysis solution containing electrolytes and glucose. No teratogenic effects are reported as it is not systemically absorbed. However, maternal metabolic disturbances during dialysis (e.g., hypotension, electrolyte shifts) may pose risks. In the first trimester, teratogenicity is unlikely. In second and third trimesters, risks include fetal hypoperfusion from maternal hypotension. No specific fetal malformations attributed to the solution itself. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to any component","Severe metabolic alkalosis","Uncorrected electrolyte imbalances","Contraindications to CRRT (e.g., severe coagulopathy, active bleeding)"]
| Precautions | ["Monitor electrolyte levels, acid-base balance, and fluid status closely.","Risk of electrolyte imbalance, hyper/hypokalemia, hyper/hypocalcemia, metabolic alkalosis or acidosis.","Use with caution in patients with severe metabolic alkalosis.","Do not administer intravenously directly; only for use in CRRT circuits."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, electrolyte levels (including potassium, sodium, calcium, magnesium, bicarbonate), glucose, acid-base status, and fluid balance throughout dialysis. Fetal monitoring includes continuous fetal heart rate monitoring during dialysis if viable, and assessment of uterine activity. Evaluate fetal growth and amniotic fluid volume regularly. |
| Fertility Effects | No direct effects on fertility are known for Prismasol B22GK 4/2.5. However, underlying renal disease and dialysis therapy may affect fertility due to hormonal imbalances and uremic milieu. |